

KPhA Immunization Update 2025

Amanda Applegate
PharmD, BCACP

Kentucky Pharmacy Education and Research Foundation, Inc. is accredited by ACPE as a provider of continuing pharmacy education.

ACPE UAN 0143-9999-25-064-Lo6-P/T

Disclosures

Faculty

Amanda Applegate, faculty for this activity, has no relevant financial relationships with ineligible companies to disclose.

Planners

None of the planners for this activity have any relevant financial relationships with ineligible companies to disclose.



Objectives: Pharmacists

- Describe trends in immunization rates across the state of Kansas
- Evaluate safety and efficacy of recently approved and upcoming vaccines
- Apply recent changes in ACIP immunization recommendations to your patient population
- Evaluate immunization resources for educating providers and patients

Objectives: Technicians

- Describe trends in immunization rates across the state of Kansas
- Identify recently approved vaccines
- Explain current COVID-19 and influenza recommendations
- Evaluate immunization resources for educating providers and patients

Pre-test

1. In the United States in 2025, most cases of measles had an unvaccinated or unknown vaccine status. How many doses of MMR or MMRV are routinely recommended for all children?

- A. 1
- B. 2
- C. 3
- D. 0

Pre-test

2. Starting at what age should adults who are at increased risk of severe RSV disease receive a single dose of RSV vaccine?

- A. 50
- B. 55
- C. 60
- D. 65


Immunization Rates



7


Kansas Immunization Rates

REQUIRED Vaccine Coverage by School District for 2023-2024 Academic Year



8

Kansas Immunization Rates



Paperwork and Legal Notes



Documentation Requirements

- Date of administration
- Vaccine manufacturer
- Vaccine lot number
- Name and title of person who administered vaccine
- Address of the facility where permanent record resides
- Vaccine information statement (VIS)
 - VIS Date
 - Date VIS given to patient/parent/guardian

Dates of Current Vaccine Information Statements (VISs) as of May 29, 2025

Check your supply of VISs against this list. If you have outdated VISs, get current versions at www.immunize.org/vaccines/vis/

Adenovirus	1/8/20	MMRV	1/31/25
Anthrax	1/8/20	Multi-vaccine	7/24/23
COVID-19	1/31/25	PCV	5/29/25
Cholera	1/31/25	PPSV23	5/29/25
Dengue	1/31/25	Polio	1/31/25

Medical Billing Requirements

- Confirms the provider has certified the medical necessity and reasonableness for service(s) submitted
- Should contain a confirmation of review statement
 - "Reviewed by..."
 - "Signed by..."
 - "Verified by..."
- Needs to be legible and/or pharmacy should maintain a signature log to match signature with typed name


Public Readiness and Emergency Preparedness (PREP) Act


- 12th Amendment, effective through December 31, 2029
 - Pharmacists, pharmacy interns, and qualified pharmacy technicians
 - Patients 3 years and older
 - COVID & influenza only
 - Tests & vaccinations

i. The vaccine must be authorized, approved, or licensed by the FDA;

ii. Vaccination must be ordered and administered according to CDC's/ACIP's COVID-19 vaccine recommendation(s)

Vaccine approval process





Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices

- "Federal advisory committee that develops recommendations on the use of vaccines in the civilian population of the United States"
 - Voting members
 - Up to 19 medical professionals
 - 1 consumer representative knowledgeable about social/community aspects of immunization programs
 - 8 non-voting ex officio members from federal agencies
 - 31 liaison members representing professional societies

What's Next?

- American Health Insurance Providers and the Alliance of Community Health Plans affirmed their commitment to covering this fall's vaccinations
- Kansas statute does not require following a specific guideline
- Does your physician protocol allow for guideline flexibility?

17

Health Alert Network (HAN)

- CDC and KDHE's primary method of sharing cleared information about urgent public health incidents with public health, clinicians, and labs
- **Health Alert:** Highest level of importance about a public health incident.
- **Health Advisory:** Important information about a public health incident.
- **Health Update:** Updated information about a public health incident.

CDC



KDHE

18

Chikungunya




Chikungunya Vaccine Schedule

- Live attenuated (Ixchiq, Valneva) FDA approved November 2023 for 18 years of age and older
 - Safety signal detected – serious adverse events with Ixchiq in adults >60 years, use has been paused
- Virus-like particle (Vimkuna, Bavarian Nordic) FDA approved February 2025 for 12 years of age and older
- ACIP recommended for people traveling to an area with a chikungunya outbreak and lab workers who might be exposed to the virus; consider for moving or extended travel to an area without risk
 - ACIP added Vimkuna April 2025

COVID-19




From July 2024 – April 2025, a period that included a high severity influenza season¹, more infants <1 and adults ≥75 had hospitalizations associated with COVID-19 than influenza.



Cumulative hospitalization rates with laboratory-confirmed SARS-CoV-2 and influenza hospitalizations — RESP-NET, July 2024–April 2025. Note that influenza surveillance is conducted from October–April annually. Data source: <https://www.cdc.gov/resp-net/dashboard/>. Note that rates are not adjusted for testing nor limited to admissions where the respiratory infection is the likely primary reason for admission. ¹<https://www.cdc.gov/flu/php/surveillance/in-season-severity.html>

Total number of COVID-19- and Influenza-associated deaths^{1,2}, among ages 0–17 years in July 2024–June 2025, United States




1. Provisional data

2. Underlying cause of death Source: Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System, Provisional Mortality on CDC WONDER Online Database. Data are from the final Underlying Cause of Death Files, provisional data for 2024 and provisional and partial data for 2025, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Number of deaths includes influenza codes (J09-J11) or COVID-19 code (U07.1) as the underlying cause of death. <http://wonder.cdc.gov/mcd-icd10-provisional.html>, accessed June 20, 2025

Note: Estimates of pediatric influenza deaths reported to CDC can be found here: <https://www.cdc.gov/fluview/surveillance/2025-week-15.html>. Estimates will vary due to differences in reporting methods and timeframes used.

Viruses that have predominated since January 2025 are all JN.1 descendants.



New COVID-19 Vaccine Option

- Low dose mRNA (mNexspike, Moderna) – 10 µg/0.2mL
- Approved for those who have previously received a COVID vaccine
 - 65 years and older
 - 12-64 years at high risk for severe COVID-19
- Storage – prefilled syringe
 - Frozen to expiration date
 - Fridge 90 days
 - Room temp 24h

FDA, Package Insert – mNexspike <https://www.fda.gov/media/156728/attachment>
Moderna, Relative vaccine efficacy against COVID-19 <https://products.modernatx.com/mnexspike/efficacy>

25

COVID-19 Notes

FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis Following Vaccination

June 25, 2025

FDA Safety Communication


Purpose: To inform the public and healthcare providers that FDA has required and approved updates to the Prescribing Information for [Comirnaty](#) (COVID-19 Vaccine, mRNA) manufactured by Pfizer Inc. and [Spikevax](#) (COVID-19 Vaccine, mRNA) manufactured ModernaTX, Inc. to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines.

FDA, FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis Following Vaccination, June 25, 2025.

26

Myocarditis Following mRNA COVID-19 Vaccination Among People Ages 12–39 Years in the Vaccine Safety Datalink

Incidence of myocarditis within 7 days of vaccination per million mRNA vaccine doses administered



- Rates peak at age 16-17 years and are higher in males
- Myocarditis rare in children aged <12 years and adults aged ≥50 years

*Statistically significant increased rate ratio in vaccinated concurrent comparator analysis. Source: CDC Immunization Safety Office


22

Meyer, S. Update on CDC's COVID-19 Vaccine Safety Monitoring. ACIP Meeting, June 2025.

27

Risks of myocarditis in the 1–28 days after COVID–19 vaccines or SARS–CoV–2

Study period: Study period: 1 December 2020 to 15 December 2021



Patone M et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. August 2022.

28

Table 3. Associations Between Clinical Outcomes and Myocarditis Groups Over 18 Months

Outcome	Postvaccine myocarditis (n = 558)		Post-COVID-19 myocarditis (n = 298)		Conventional myocarditis (n = 3779)	
	No. of events (%)	Weighted hazard ratio ^a	No. of events (%)	Weighted hazard ratio ^a	No. of events (%)	Weighted hazard ratio ^a
Rehospitalization for myopericarditis	18 (3.2)	0.75 (0.40-1.42)	12 (4.0)	1.07 (0.53-2.13)	220 (5.8)	1
Cardiovascular event (excluding myopericarditis)	15 (2.7)	0.54 (0.27-1.05)	22 (7.4)	1.01 (0.62-1.64)	277 (7.3)	1
Heart failure, heart rhythm and conduction disorders, cardiomyopathy ^b	6 (1.1)	0.53 (0.07-4.28)	11 (3.7)	1.23 (0.58-2.63)	132 (3.5)	1
Hospitalization for any cause	68 (12.2)	0.69 (0.50-0.94)	63 (21.1)	1.04 (0.73-1.48)	739 (19.6)	1
Death from any cause	1 (0.2)		4 (1.3)		49 (1.3)	1
Composite outcome 1 ^c	32 (5.7)	0.55 (0.36-0.86)	36 (12.1)	1.04 (0.70-1.52)	497 (13.2)	1
Composite outcome 2 ^c	75 (13.4)	0.64 (0.48-0.85)	76 (25.5)	1.03 (0.75-1.40)	874 (23.1)	1


Benvenuto L et al. Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies. JAMA. August 2024.

29

COVID-19 Recommendations

- FDA – any new COVID vaccine approval must undergo placebo-controlled clinical trials focusing on symptomatic illness to earn a general recommendation

- CDC has removed recommendation for COVID-19 vaccine for healthy children and pregnant women from routine schedules



30

COVID-19 notes

- ACIP COVID workgroup discussions only – NOT OFFICIAL POLICY


6-23 months	≥65 years
• Universal recommendation • Age-appropriate series	• Universal recommendation • 2 doses
2-64 years	≥6 months, moderate to severe immunocompromise
• Anyone at high risk of severe COVID-19, including during pregnancy • Anyone with high risk of exposure • Shared clinical decision making for everyone else	• Universal recommendation • 2 doses

31

Influenza



Influenza Disease Burden Varied by Season



Dugan V. Estimates of influenza burden and burden averted through vaccination. ACIP Meeting, June 2025. CDC, FluVaxView. Accessed June 2, 2025.

33

Kansas Pharmacists Association // 2025 Annual Meeting & Trade Show August 22-24 // Lawrence, KS

Influenza Notes

- Trivalent vaccine
- Recombinant influenza vaccination (Flublok, Sanofi)
 - FDA approved age range increase to 9 years and older March 2025
- ACIP affirmed existing recommendation that everyone aged 6 months and older should receive a flu shot
 - Preferential recommendation for high dose (Fluzone High Dose, Sanofi), adjuvanted (Fluad, Seqiris), or recombinant influenza (Flublok, Sanofi) vaccinations for all persons aged 65 years and older
 - Avoid vaccinating during July/August for most adults



<https://www.fda.gov/media/179778/download?attachment>
 Gronsopel LA, Ferdinands JM, Blanton LH, Broder KR, Lohr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024 Aug 29;73(5):1-25. doi: 10.15585/mmwr.r7305a1. PMID: 39197095; PMCID: PMC11501009.

34

New Influenza Vaccine Option

- Live attenuated influenza vaccine (FluMist, AstraZeneca) *for home delivery and self/caregiver administration*
- Nasal spray flu vaccine
- Indicated for ages 2-49 years



- Disposal via mail-back

AstraZeneca. FluMist Home Delivery. <https://www.flumist.com/home-orders.html>

35

Influenza Notes

- ACIP voted to remove flu shots containing thimerosal from the annual influenza recommendation
- What is thimerosal?
 - Ethylmercury-based preservative 
 - Found in cosmetics, eye drops, disinfectants, and other medications
- Methylmercury found in fish 
- Multi-dose vials affected


<https://www.fda.gov/media/179778/download?attachment>
Gronskop LA, Ferdinands JH, Blanton LH, Broder KR, Lohr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024 Aug 29;73(5):1-25. doi: 10.15585/mmwr.r7305a1. PMID: 39197095; PMCID: PMC11501009.

36

Highly Pathogenic Avian Influenza (HPAI)

- No known person to person spread
- 70 total cases
- 7 probable cases
- 1 death
- Aug 1, 2025

Confirmed Human Cases of HPAI since 2024



Total cases



- 41 – Dairy herds
- 24 – Poultry farms
- 2 – Other animal
- 3 – Unknown source

CDC, H5 Bird Flu: Current Situation. <https://www.cdc.gov/bird-flu/situation-summary/index.html?cove-tab=0>

37

Kansas Pharmacists Association // 2025 Annual Meeting & Trade Show August 22-24 // Lawrence, KS

Invasive pneumococcal disease (IPD)



Invasive pneumococcal disease

- ACIP recommends a single dose of any PCV vaccine for all PCV-naïve adults aged ≥ 50 years
- 32-54% of adults aged 50-64 years had ≥ 1 qualifying risk
- 37% of adults aged 50-64 years with a risk were vaccinated
- IPD rates in black adults peak at 55-59 years

Included in vaccine
Not included in vaccine

	Serotype																																			
Vaccine	1	3	4	5	6A	6B	7F	9V	14	18C	19A	19F	23F	22F	33F	8	10A	11A	12F	15B	2	9N	17F	20	15A	15C	16F	23A	23B	24F	31	35B				
PCV21																																				
PPSV23																																				
PCV20																																				
PCV15																																				

Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥ 50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep 2025;74:3-8. DOI: <https://doi.org/10.15585/mmwr.mm7403a3>.

39

Invasive pneumococcal disease

Included in vaccine
Not included in vaccine


	Serotype																																			
Vaccine	1	3	4	5	6A	6B	7F	9V	14	18C	19A	19F	23F	22F	33F	8	10A	11A	12F	15B	2	9N	17F	20	15A	15C	16F	23A	23B	24F	31	35B				
PCV21																																				
PPSV23																																				
PCV20																																				
PCV15																																				

- Consider PCV20 or PCV15 + PPSV23 in areas where serotype 4 causes $\geq 30\%$ of IPD cases or in specific underlying conditions:
 - Alcoholism
 - Chronic lung disease
 - Cigarette smoking
 - Homelessness
 - Injection drug use
 - Alaska
 - Colorado
 - Navajo Nation
 - New Mexico
 - Oregon

Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥ 50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep 2025;74:3-8. DOI: <https://doi.org/10.15585/mmwr.mm7403a3>.

40

PneumoRecs VaxAdvisor



PneumoRecs VaxAdvisor	
Patient Characteristics	
Age	19 through 49 years
PCV15, PCV20, or PCV21	No prior doses
Risk Factors	Yes
PPSV23	Has received prior doses
PCV13	No prior doses
Recommendation	
Give one dose of PCV15, PCV20, or PCV21 at least 1 year after their last dose of PPSV23. Regardless of which vaccine is used (PCV15, PCV20, or PCV21), their pneumococcal vaccinations are complete.	


PneumoRecs VaxAdvisor	
Patient Characteristics	
Age	≥50 years
PCV15, PCV20, or PCV21	No prior doses
PPSV23	Has received prior doses
PCV13	No prior doses
Recommendation	
Give one dose of PCV15, PCV20, or PCV21 at least 1 year after the last dose of PPSV23. Regardless of which vaccine is used (PCV15, PCV20, or PCV21), their pneumococcal vaccinations are complete.	

41

Measles



8/17/25




Yearly measles cases

as of August 5, 2025

2000–Present*

1985–Present*



https://www.cdc.gov/measles/data-research/index.html

Total cases: 285
Hospitalizations:
114 (40%)


Age

<5 years: 120 (42%)
5-19 years: 88 (31%)
≥20 years: 77 (27%)

Vaccination Status

Unvaccinated or
unknown: 89%
One MMR dose: 7%
Two MMR doses: 4%

US Measles Cases 2024



<https://www.cdc.gov/measles/data-research/index.html>

45

Total cases: 1356
Hospitalizations:
171 (13%)
Deaths: 3


Age

<5 years: 386 (28%)
5-19 years: 501 (37%)
≥20 years: 462 (34%)

Vaccination Status

Unvaccinated or
unknown: 92%
One MMR dose: 4%
Two MMR doses: 4%

US Measles Cases 2025



August 6, 2025

<https://www.cdc.gov/measles/data-research/index.html>

46

Approximate timeline

- Day 0 – Exposure
 - Day 10-14 – Prodrome
 - 3 C's – cough, coryza, conjunctivitis
 - Fever – 103°-105°
 - Koplik spots on mucous membranes
 - Days 14-20 – Rash
 - Head → neck → trunk → limbs
 - Day 21 – 2-3 years - Post measles
 - Immune amnesia
- Contagious 4 days before rash and 4 days after rash appears

49

Measles Vaccinations

MMRII (Merck)

- Live
- 0.5mL
- Admin subQ or IM
- ≥12 months
- Vaccine frozen, diluent fridge or room temp
- Contains gelatin

ProQuad- MMRV (Merck)

- Live
- 0.5mL
- Admin subQ or IM
- 12 mo – 12 years
- Vaccine frozen, diluent fridge or room temp
- Contains gelatin

• Priorix (GSK)

- Live
- 0.5mL
- Admin subQ
- ≥12 months
- Vaccine refrigerated, diluent fridge or room temp

50


Routine Measles Vaccination Recommendations	• Children • 2 doses MMR or MMRV recommended for all children • First dose at 12-15 months • Second dose at 4-6 years (before school) • Adults • One dose is recommended for all adults ≥ 18 years if no previous evidence of immunization or immunity • Two doses 28 days apart are recommended for adults working in healthcare or attending college
---	--

51

• Children • Early dose at 6-11 months • Subsequent dose at 12-15 months • Final dose at 4-6 years (before school) • Children >12 months with no history of MMR vaccine should receive one dose immediately then another dose after 28 days	Teens & Adults • One dose is recommended for all who have received one previous dose of any MMR vaccine • Two doses 28 days apart are recommended for all with no history of vaccination	Outbreak Measles Vaccination Guidance
--	---	---

52

FIGURE. Geographic distribution of suspected alpha-gal syndrome cases* per 1 million population per year — United States, 2017–2022



53

Kansas Pharmacists Association // 2025 Annual Meeting & Trade Show August 22-24 // Lawrence, KS

Bacterial meningitis



54

Meningococcal Vaccine Schedule

- **MenACWY** recommended for *all* healthy persons aged 11-18 years
 - Single dose at 11-12 years
 - Booster dose at 16 years
- **MenB** recommended for healthy persons 16-23 years based on *shared clinical decision making*
 - 2 dose series



CDC Pink Book; Teen image from Pixabay; Meningitis image from testimony submitted by bacterial meningitis survivor to Kansas Senate – March 22, 2021.

55

Meningococcal Vaccine Schedule

- MenABCWY (Penbraya, Pfizer) FDA approved October 2023
- MenABCWY (Penmenvy, GSK) FDA approved February 2025
- ACIP recommended for people aged 10-25 years who are receiving MenACWY and MenB vaccines at the same visit
 - ACIP added Penmenvy April 2025
- Use same manufacturer for second MenB vaccine when due
 - Penbraya → Trumenba
 - Penmenvy → Bexsero, 6 months later

Collins et al. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of ACIP—US, 2023. MMWR 2024;73:345–350.
DOI: <http://dx.doi.org/10.15585/mmwr.mm7315a4>

56

Meningococcal Vaccine Schedule

	Recommendation with separate ACWY and B vax	Recommendation with ABCWY vax
11-12 year old	 MenACWY Dose 1	 MenACWY
16 years and older	 MenACWY Dose 2	 MenABCWY (Same mfg!)
	 MenB Dose 1	 MenB (Same mfg!)
	 MenB Dose 2	

57

Respiratory syncytial virus (RSV)



58

RSV Vaccine Recommendations – Older Adults

- All adults aged ≥ 75 years and adults aged 60-74 years at increased risk of severe RSV disease should receive a single dose of RSV vaccine
- **Adults aged 50-59 years at increased risk of severe RSV disease should receive a single dose of RSV vaccine**

Recombinant protein (Arexvy, GSK)	Recombinant protein (Abrysvo, Pfizer)	mRNA (mRESVIA, Moderna)
FDA approved for 50 years and older	FDA approved for 18 years and older	FDA approved for 18 years and older

ACIP Meeting: RSV – Older Adults, April 2025.
FDA Package inserts – Arexvy, Abrysvo, mRESVIA. Accessed June 2025.

59

Increased risk for severe RSV – 60-74 years

	Chronic heart disease (eg. heart failure, coronary artery disease, congenital heart disease)		Diabetes with CKD and/or end organ damage (eg. neuropathy, retinopathy) or treatment with insulin or SGLT2i
	Chronic lung disease (eg. COPD, emphysema, asthma, cystic fibrosis, interstitial lung disease)		Neurologic or neuromuscular conditions causing impaired airway (eg. poststroke dysphagia, ALS, muscular dystrophy)
	End-stage renal disease, hemodialysis, other renal replacement therapy		Chronic hematologic conditions (eg. sickle cell disease, thalassemia)
	Moderate or severe immune compromise		Chronic liver disease (eg. cirrhosis)
	Severe obesity (BMI ≥ 40 kg/m ²)		Residence in a nursing home
Other chronic medical conditions or risk factors that a healthcare provider determines would increase the risk for severe disease (eg. frailty, concern for undiagnosed chronic conditions, residency in a remote or rural community where transportation of patients for escalation of medical care is challenging)			

Britton A, Roper LE, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥ 60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep. ePub: 6 August 2024. DOI: <https://dx.doi.org/10.15585/mmwr.mm7332e1>

60

New RSV Antibody Option - Infants

- Nirsevimab (Beyfortus, Pfizer) FDA approved July 2023
 - Recommended for infants <8 months who are born during or entering their first RSV season (October-March) if there is not evidence of vaccination during pregnancy
 - Recommended for children aged 8-19 months who are at increased risk and entering their second RSV season
- Clesrovimab (Enflonsia, Merck) FDA approved June 2025
 - Recommended for infants <8 months who are born during or entering their first RSV season (fall through spring) if there is not evidence of vaccination during pregnancy

<https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html>
ACIP Meeting, June 2025

61

Summary of RSV prevention product effectiveness (PE) among infants in their first RSV season, 2024–2025

Outcome	Product	CDC Network	Product Efficacy*/Effectiveness (95% CI)	
RSV-associated ED visit	Nirsevimab	VISION	63 (56-69)	
		NVSN	76 (55-87)	
		Clinical Trial	Not Applicable	
	Maternal Vaccine	VISION	54 (35-67)	
		Clinical Trial	Not Applicable	
RSV-associated hospitalization	Nirsevimab*	VISION	79 (67-87)	
		NVSN	82 (71-88)	
		Clinical Trial	81 (62-90)	
	Maternal Vaccine†	VISION	79 (55-90)	
		NVSN	70 (28-88)	
		Clinical Trial	57 (15-80)	
RSV-associated Intensive Care Unit (ICU) admission	Nirsevimab*	VISION	82 (57-93)	
		NVSN	88 (63-96)	
		Overcoming	80 (73-85)	
		Clinical Trial	90 (16-99)	

*Jones et al. *MMWR* 2023. Available: <https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm>


†Kampmann et al. *NEJM* 2023. Available: <https://www.nejm.org/doi/full/10.1056/NEJMoa2216480>

0 20 40 60 80 100
Vaccine Effectiveness (%)

62

ACIP Meeting. Effectiveness and impact of RSV prevention products in infants during the 2024–2025 RSV season. June 2025.

Cumulative adjusted RSV-associated hospitalization rates in 2024–25 were compared to seasons before product introduction by age group



Bar labels indicate cumulative laboratory-confirmed RSV-associated hospitalizations per 1,000 children as of April 30 (RSV-NET) or March 31 (NVSN) each season. Rates use U.S. population denominators. RSV-NET rates are adjusted to account for RSV underdetection because of testing practices and test sensitivity. NVSN rates are adjusted to account for weeks with <7 days of surveillance, the proportion of eligible children not enrolled, sensitivity of respiratory syncytial virus reverse-transcription polymerase chain reaction testing compared to serology, and each site's estimated market share of acute respiratory illness hospitalizations by age. Error bars denote 95% confidence intervals (95% CI).

ACIP Meeting: Effectiveness and impact of RSV prevention products in infants during the 2024–2025 RSV season. June 2025.

63

Kansas Pharmacists Association // 2025 Annual Meeting & Trade Show August 22-24 // Lawrence, KS

Immunization Resources



64



American Pharmacists Association

Immunization Neighborhood

- Collaboration
-
- Coordination
-
- Communication

65

Patient Resources

The Meg Foundation

- Decreasing pain & anxiety for painful procedures in children
- Poke Plans by age
- SuperMeg Poke Planner app



Pokes are a problem.



What's Buzzy?
Buzzy's vibrations block the pain signal so you don't have to feel the poke!



What's numbing cream?
It's a cream that you put on 30-60 minutes before the poke that numbs your skin!



What's Shotblocker?
Shotblocker is a plastic device with little "nubs" that distract your nerves. Your brain feels the nubs, but not the poke!

66

Patient Resources

Does mRNA Alter DNA?

By Heather Simpson,
Back to the Vax

One of the biggest rumors floating around about the mRNA inside of the Moderna and Pfizer COVID-19 vaccines is that the mRNA can enter a cell and alter your DNA. It seems like it could, but it can't.

Nope, it can't!

What exactly is rushed and something being prioritized and expedited. The word "rushed" implies steps were missed. Say you are at a restaurant and you order a cheeseburger.

Somehow, your cheeseburger was forgotten and the kitchen made the rest of your table's orders. It ensures and they quickly throw your order to the back of the line. You get your burger.

VACCINE FEARS OVERTURNED BY FACTS



Were COVID-19 Vaccines Rushed?

By Lydia Greene, Back to the Vax

Do Vaccines Cause Autism?

By Lydia Greene, Back to the Vax

Short Answer: No. Wow, that was easy. (kidding).

Long Answer: Here is how I realized that vaccines do not cause autism from the lens of a former anti-vax parent. I have 3 children, and I stopped vaccinating when my oldest was just 4 months old. My next 2 children were completely unvaccinated. Being in the anti-vax crowd led me to have the wrong idea of what autism is. Parents in

67

Kansas Pharmacists Association // 2025 Annual Meeting & Trade Show August 22-24 // Lawrence, KS

Post-test

1. In the United States in 2025, most cases of measles had an unvaccinated or unknown vaccine status. How many doses of MMR or MMRV are routinely recommended for all children?

- A. 1
- B. 2
- C. 3
- D. 0

Post-test

2. Starting at what age should adults who are at increased risk of severe RSV disease receive a single dose of RSV vaccine?

- A. 50
- B. 55
- C. 60
- D. 65

THANK YOU!



Questions?

You can reach me at

amanda@ksrx.org
cell: 316.259.4680
office: 785.228.2327

Collect Your CE

The Lecture Panda
code for this session is:
{code here}

*All course credits from this
conference must be submitted by
Oct. 15, 2025.*